Table 5.
Group 1 |
Group 2 |
Group 3 |
P-value* | ||||
---|---|---|---|---|---|---|---|
No-SDB partner of No-SDB | Min-Max | No-SDB partner of SDB | Min-Max | SDB partner of SDB | Min-Max | ||
N | 46 | 42 | 22 | ||||
Age (years) | 61 | 45–80 | 63 | 47–74 | 65 | 51–84 | 0.14 |
BMI | 26† | 19–39 | 26 | 22–34 | 33 | 22–50 | 0.0001 |
RDI 4% | 1.3† | 0–4.9 | 1.8 | 0–4.9 | 18 | 11–75 | 0.0001 |
Sleep onset lat. | 12 | 0–102 | 14 | 0– 53 | 12 | 6–80 | 0.91 |
Total sleep time | 384 | 239–495 | 400 | 333–456 | 385 | 221–427 | 0.14 |
Sleep efficiency | 84 | 60–96 | 82 | 57–95 | 81 | 63–92 | 0.16 |
Stage 1 % | 5 | 1–15 | 4 | 1–10 | 5 | 2–18 | 0.46 |
Stage 2 % | 54 | 23–70 | 55 | 30–71 | 60 | 38–80 | 0.44 |
Stage 3 and 4 % | 17 | 1–53 | 21 | 5–47 | 14 | 0.3–47 | 0.10 |
REM% | 23 | 9–30 | 20.3 | 8–35 | 21 | 7–35 | 0.07 |
Arousal index | 13‡ | 5–34 | 13.8§ | 5–27 | 19 | 6–54 | 0.002 |
Habitual SOL | 15 | 2–60 | 15 | 4–120 | 15 | 2–45 | 0.94 |
Habitual TST | 465 | 195–540 | 420 | 300–600 | 480 | 300–720 | 0.60 |
ESS | 8 | 0–14 | 6 | 0–15 | 7 | 1–19 | 0.52 |
Physical function | 50 | 28–50 | 50δ | 28–50 | 44 | 17–50 | 0.03 |
Bodily pain | 74 | 32–100 | 84 | 0–100 | 72 | 31–100 | 0.54 |
General health | 77 | 47–100 | 82 | 20–100 | 77 | 32–100 | 0.86 |
Vitality | 65 | 30–100 | 73 | 45–90 | 65 | 25–90 | 0.18 |
Social function | 100 | 50–100 | 100 | 25–100 | 100 | 50–100 | 0.78 |
Role-emotional | 100 | 0–100 | 100 | 0–100 | 100 | 0–100 | 0.49 |
Mental health | 84 | 40–100 | 84 | 32–100 | 84 | 56–96 | 0.69 |
P-value for Kruskal-Wallis test. ESS (Epworth Sleepiness Scale).
P-value < 0.0001 for Wilcoxon rank-sum (Mann-Whitney) test between groups 1 and 3.
P-value < 0.0167 for Wilcoxon rank-sum (Mann-Whitney) test between groups 1 and 3.
P-value < 0.0001 for Wilcoxon rank-sum (Mann-Whitney) test between groups 2 and 3.
P-value < 0.01 for Wilcoxon rank-sum (Mann-Whitney) test between groups 2 and 3.